Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Basket Study of Brigatinib in Patients with Advanced Solid Tumors with ROS1 Rearrangement

X
Trial Profile

Basket Study of Brigatinib in Patients with Advanced Solid Tumors with ROS1 Rearrangement

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brigatinib (Primary)
  • Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms Barossa study
  • Sponsors Takeda Pharma
  • Most Recent Events

    • 13 Sep 2022 Primary endpoint has been met (objective response rate) , Results presented at the 47th European Society for Medical Oncology Congress
    • 13 Sep 2022 Results (n=28) reporting efficacy and data from cohort 1 of this trial in which TKI-naive ROS1-rearranged NSCLC patients were enrolled presented at the 47th European Society for Medical Oncology Congress
    • 14 Sep 2021 Results (n=19) of cohort 2 were presented at the 2021 World Conference on Lung Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top